IVIXF OTC

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts. It holds an R&D agreement with the Hudson Institute of Medical Research, partnering on several projects related to the Photosoft technology for cancer treatment. Additionally, Invion has established a research pact with the Peter MacCallum Cancer Centre to carry out pre-clinical and in-vitro studies focusing on its IVX-PDT photodynamic therapy for ano-genital cancers, including penile and anal forms. Established in 2000, Invion Limited is based in Melbourne, Australia.